Fund shareholders of Arrowhead Pharmaceuticals Inc
ISIN US04280A1007 · United States · LEI 549300O3CSB8T7OZ3D66
- Fund shareholders
- 416
- Of which ETFs
- 94 322 other funds
- Value held
- 3.3B $ 949.6K € · 120.1M SEK
- Share of capital
- 36.5 % of 141.3M shares on Jul 30, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Strategic Allocation: Conservative Fund American Century Strategic Asset Allocations Inc | 201 | 14.8K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 182 | 11.4K $ | 0.19 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 136 | 8.6K $ | 0.04 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 128 | 8K $ | 0.26 % | 0.00 % | as of Mar 31, 2026 ↗ |
| E*TRADE No Fee Total Market Index Fund E Trade Trust | 124 | 9.1K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Mid-Cap 1.5x Strategy Fund Rydex Variable Trust | 117 | 7.3K $ | 0.22 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Sector Rotation Fund Meeder Funds | 102 | 6.4K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Avantis Total Equity Markets ETF American Century ETF Trust | 73 | 4.6K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Lazard Enhanced Opportunities Portfolio LAZARD FUNDS INC | 45 | 2.8K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Abacus FCF Small Cap Leaders ETF Abacus FCF ETF Trust | 44 | 3.2K $ | 0.26 % | 0.00 % | as of Apr 30, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 43 | 2.7K $ | 0.24 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 35 | 2.2K $ | 0.08 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Goldman Sachs MSCI World Private Equity Return Tracker ETF Goldman Sachs ETF Trust | 21 | 1.3K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| NPF Core Equity ETF Elevation Series Trust | 3 | 220.4 $ | 0.00 % | as of Apr 30, 2026 ↗ | |
| PATRIVAL, FI PATRIVALOR, SGIIC, S.A. | 474.8K € | 0.71 % | as of Dec 31, 2025 ↗ | ||
| PATRIBOND, FI PATRIVALOR, SGIIC, S.A. | 474.8K € | 0.60 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Global X Genomics & Biotechnology ETF GLOBAL X FUNDS | 5.69 % | as of Feb 28, 2026 ↗ |
| Amplify Weight Loss Drug & Treatment ETF Amplify ETF Trust | 4.96 % | as of Mar 31, 2026 ↗ |
| iShares Neuroscience and Healthcare ETF iShares Trust | 4.41 % | as of Apr 30, 2026 ↗ |
| ALGER HEALTH SCIENCES FUND ALGER FUNDS | 4.04 % | as of Apr 30, 2026 ↗ |
| ALGER SMALL CAP FOCUS FUND ALGER FUNDS | 3.49 % | as of Apr 30, 2026 ↗ |
| Invesco Biotechnology & Genome ETF Invesco Exchange-Traded Fund Trust | 3.28 % | as of Apr 30, 2026 ↗ |
| Alger Mid Cap 40 ETF Alger ETF Trust | 2.85 % | as of Mar 31, 2026 ↗ |
| ROBO Global Healthcare Technology and Innovation ETF EXCHANGE TRADED CONCEPTS TRUST | 2.56 % | as of Apr 30, 2026 ↗ |
| Invesco S&P Midcap 400 Pure Growth ETF Invesco Exchange-Traded Fund Trust | 2.32 % | as of Apr 30, 2026 ↗ |
| ClearBridge Small Cap Fund Legg Mason Global Asset Management Trust | 1.93 % | as of Apr 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 412 | +105 | 51,416,594 | +2.6 % |
| 2026Q1 | 307 | +60 | 50,102,531 | +7.9 % |
| 2025Q4 | 247 | +21 | 46,448,798 | +3.3 % |
| 2025Q3 | 226 | +12 | 44,948,510 | +3.3 % |
| 2025Q2 | 214 | -25 | 43,498,039 | +14.3 % |
| 2025Q1 | 239 | -30 | 38,048,587 | -11.1 % |
| 2024Q4 | 269 | -11 | 42,779,156 | +3.0 % |
| 2024Q3 | 280 | -10 | 41,528,055 | -3.0 % |
| 2024Q2 | 290 | +9 | 42,824,156 | +10.5 % |
| 2024Q1 | 281 | -15 | 38,771,024 | +0.5 % |
| 2023Q4 | 296 | 38,593,622 |
Institutional managers
423 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 18,161,519 | 1.1B $ | as of Mar 31, 2026 |
| Avoro Capital Advisors LLC | 10,699,999 | 670.9M $ | as of Mar 31, 2026 |
| FMR LLC | 7,266,652 | 455.6M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 6,496,130 | 407.3M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 4,278,828 | 274.5M $ | as of Mar 31, 2026 |
| FRED ALGER MANAGEMENT, LLC | 3,342,493 | 209.6M $ | as of Mar 31, 2026 |
| Invesco Ltd. | 3,280,647 | 205.7M $ | as of Mar 31, 2026 |
| Vestal Point Capital, LP | 2,275,000 | 142.6M $ | as of Mar 31, 2026 |
| BAKER BROS. ADVISORS LP | 1,992,783 | 124.9M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 1,739,923 | 109.1M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 1,655,837 | 103.8M $ | as of Mar 31, 2026 |
| Siren, L.L.C. | 1,615,476 | 101.3M $ | as of Mar 31, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1,573,297 | 98.6M $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 1,436,990 | 90.1M $ | as of Mar 31, 2026 |
| UBS Group AG | 1,336,271 | 83.8M $ | as of Mar 31, 2026 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,330,996 | 83.5M $ | as of Mar 31, 2026 |
| Pictet Asset Management Holding SA | 1,273,266 | 79.6M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,192,085 | 74.7M $ | as of Mar 31, 2026 |
| Driehaus Capital Management LLC | 1,190,335 | 74.6M $ | as of Mar 31, 2026 |
| D. E. Shaw & Co., Inc. | 1,183,838 | 74.2M $ | as of Mar 31, 2026 |
| Fisher Asset Management, LLC | 1,113,568 | 69.8M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 1,064,455 | 66.7M $ | as of Mar 31, 2026 |
| Hood River Capital Management LLC | 1,056,534 | 66.2M $ | as of Mar 31, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1,043,732 | 65.4K $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 1,036,495 | 65M $ | as of Mar 31, 2026 |
Declared shareholders of Arrowhead Pharmaceuticals Inc
There are 4 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| BlackRock, Inc. | 12.20 % | 17,104,084 | as of Mar 31, 2026 · SCHEDULE 13G |
| FMR LLC and 1 other | 5.20 % | 7,349,107 | as of Mar 31, 2026 · SCHEDULE 13G |
| Vanguard Portfolio Management | 5.19 % | 7,269,957 | as of Mar 31, 2026 · SCHEDULE 13G |
| Vanguard Capital Management | 5.05 % | 7,081,293 | as of Mar 31, 2026 · SCHEDULE 13G |
Funds holding the debt of Arrowhead Pharmaceuticals Inc
44 funds declare 44 bond lines of this company. The table shows the 25 largest holdings. The amount is the one the fund files. It is not a share of the debt, because no regulator publishes the amount outstanding in open access.
Cite this page
Titelia. "Fund shareholders of Arrowhead Pharmaceuticals Inc". https://titelia.com/en/stocks/arrowhead-pharmaceuticals-inc-US04280A1007